| Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. | |
| | |
MedLine Citation:
|
PMID: 20093927 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The objective of this study was to compare the effects of gliclazide/metformin on glycemic control in patients with Type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. This was a prospective, open-labeled, multicentric study over 12 weeks. Patients who were diagnosed of Type 2 diabetes and were uncontrolled on monotherapy with oral hypoglycemic agents, including gliclazide and metformin, characterized by HbA1c 7% or greater and 10% or less and fasting plasma glucose (FPG) 140 mg/dL or greater were enrolled in this study. The treatment regimen was started at 80 mg gliclazide plus 500 mg metformin once a day and was titrated to the next dose level depending on the clinician's judgment, not exceeding a total daily dose of 320 mg gliclazide and 2000 mg metformin. Changes from baseline HbA1c, FPG, and postprandial glucose were examined. After 12-weeks treatment, the gliclazide + metformin combination showed improvement in metabolic control as assessed by changes in HbA1c, FPG, and postprandial glucose. The primary efficacy parameter, HbA1c, was significantly reduced to 7.35 ± 1.10 at the end of treatment from the baseline value (8.51 ± 0.77) (P < 0.001). A total of 84.35% of patients showed a 0.5% or greater reduction in HbA1c and 37.39% of patients reported less than 7% HbA1c at the end of therapy. FPG and postprandial glucose were significantly reduced at the end of therapy as compared with baseline values (P < 0.001). Moreover, the lipid profile was also improved during the treatment period. The addition of gliclazide to metformin is an effective treatment for patients inadequately controlled on sulfonylurea or metformin alone. A combination of gliclazide with metformin achieves good glycemic control and improves lipid levels with better tolerability profile. |
| | |
Authors:
|
Anil Pareek; Nitin Chandurkar; Shyamsundar Zawar; Navneet Agrawal |
Related Documents
:
|
12365817 - Insulin-sensitizing agents--thiazolidinediones (glitazones). 11060717 - Pharmacology and clinical experience with repaglinide. 19701877 - Improved metabolic control after 12-week dietary intervention with low glycaemic isomal... 2862087 - U.k. prospective diabetes study. ii. reduction in hba1c with basal insulin supplement, ... 1896517 - Improvement of hyperglycemia and hyperlipemia in streptozotocin-diabetic rats by a meth... 9214407 - Elevated cytosolic calcium and impaired proliferation of b lymphocytes in type ii diabe... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American journal of therapeutics Volume: 17 ISSN: 1536-3686 ISO Abbreviation: Am J Ther Publication Date: 2010 Nov-Dec |
Date Detail:
|
Created Date: 2010-11-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9441347 Medline TA: Am J Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 559-65 Citation Subset: IM |
Affiliation:
|
Medical Affairs & Clinical Research, Ipca Laboratories Limited, Mumbai, India. anilpareek@ipca.co.in |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pseudorenal insufficiency with isopropyl alcohol ingestion.
Next Document: Varenicline effects on cocaine self administration and reinstatement behavior.